Lv25
198 积分 2025-02-09 加入
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
24天前
已完结
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer
25天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
28天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
28天前
已完结
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
1个月前
已完结
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer
1个月前
已完结
Histologic and Immunologic Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma
3个月前
已完结
Alveolar Soft Part Sarcoma: An Updated Review
5个月前
已完结
Phase IB/II Trial with Correlative Analyses of Doxorubicin plus Durvalumab Combination in Patients with Advanced Soft Tissue Sarcoma
6个月前
已完结
皖公网安备34019202002308
